<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bi P</submitter><funding>NICHD NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Welch Foundation</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><pagination>323-327</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5502127</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>356(6335)</volume><pubmed_abstract>Skeletal muscle formation occurs through fusion of myoblasts to form multinucleated myofibers. From a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) loss-of-function screen for genes required for myoblast fusion and myogenesis, we discovered an 84-amino acid muscle-specific peptide that we call Myomixer. Myomixer expression coincides with myoblast differentiation and is essential for fusion and skeletal muscle formation during embryogenesis. Myomixer localizes to the plasma membrane, where it promotes myoblast fusion and associates with Myomaker, a fusogenic membrane protein. Myomixer together with Myomaker can also induce fibroblast-fibroblast fusion and fibroblast-myoblast fusion. We conclude that the Myomixer-Myomaker pair controls the critical step in myofiber formation during muscle development.</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>Control of muscle formation by the fusogenic micropeptide myomixer.</pubmed_title><pmcid>PMC5502127</pmcid><funding_grant_id>1-0025</funding_grant_id><funding_grant_id>R01 AR067294</funding_grant_id><funding_grant_id>R01 DK099653</funding_grant_id><funding_grant_id>R01 HL130253</funding_grant_id><funding_grant_id>U54 HD087351</funding_grant_id><funding_grant_id>award301125</funding_grant_id><funding_grant_id>award301124</funding_grant_id><funding_grant_id>AR-067294, HL-130253, DK-099653, HD-087351</funding_grant_id><pubmed_authors>Bassel-Duby R</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Bi P</pubmed_authors><pubmed_authors>Ramirez-Martinez A</pubmed_authors><pubmed_authors>Shelton JM</pubmed_authors><pubmed_authors>Cannavino J</pubmed_authors><pubmed_authors>Sanchez-Ortiz E</pubmed_authors><pubmed_authors>Olson EN</pubmed_authors><pubmed_authors>McAnally JR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Control of muscle formation by the fusogenic micropeptide myomixer.</name><description>Skeletal muscle formation occurs through fusion of myoblasts to form multinucleated myofibers. From a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) loss-of-function screen for genes required for myoblast fusion and myogenesis, we discovered an 84-amino acid muscle-specific peptide that we call Myomixer. Myomixer expression coincides with myoblast differentiation and is essential for fusion and skeletal muscle formation during embryogenesis. Myomixer localizes to the plasma membrane, where it promotes myoblast fusion and associates with Myomaker, a fusogenic membrane protein. Myomixer together with Myomaker can also induce fibroblast-fibroblast fusion and fibroblast-myoblast fusion. We conclude that the Myomixer-Myomaker pair controls the critical step in myofiber formation during muscle development.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Apr</publication><modification>2024-10-17T20:15:38.069Z</modification><creation>2019-03-27T02:49:51Z</creation></dates><accession>S-EPMC5502127</accession><cross_references><pubmed>28386024</pubmed><doi>10.1126/science.aam9361</doi></cross_references></HashMap>